News | May 30, 2014

Recall Issued for Alere INRatio2 PT/INR Professional Test Strips

Results disagree with confirmed PT/INR reference test results performed by central laboratory

May 30, 2014 — Alere announced a class I recall of its INRatio2 PT/INR professional test strips, part of the Alere lNRatio2 PT/INR monitoring system (professional use) which also consists of the INRatio2 monitor. This recall is expected to cause a shortage of test strips for the Alere INRatio2 professional PT/INR testing. Alere will transition customers from the current Alere INRatio2 PT/INR professional test strip to the Alere INRatio PT/INR test strip, which is not affected by the recall and is used by patient self-testers for home INR monitoring but has also been validated for professional use.

The affected test strips were manufactured from Aug. 22, 2013, through April 2, 2014, and distributed from Aug. 26, 2013, through April 2, 2014.

The Alere lNRatio2 PT/INR monitoring system (professional use) is used for quantitative determination of international normalized ratio (INR) in fresh, capillary whole blood to monitor the effect of warfarin on clotting time (prothrombin time). The system is intended for use outside of the body (in vitro diagnostic use) and not intended to be used for screening purposes. It is also not intended for use in patients who are transitioning from heparin treatment to warfarin therapy.

Initiated in April, the recall is due to complaints of patients who had a therapeutic or near-therapeutic INR result with the Alere INRatio2 PT/INR professional test strip but a significantly higher INR result (outside of therapeutic range) when retesting was performed by a central laboratory because of deterioration in the patient’s clinical condition. Use of this affected product may cause serious adverse health consequences, including death. At the time of writing Alere San Diego received nine reports of malfunctions; six injuries and three deaths caused by bleeding.

On April 17, 2014, Alere sent an Urgent Medical Device Recall letter to all affected customers by fax, email or direct mail. The letter identified the product, problem and the actions to be taken. Customers were requested to complete and sign a Reply Form that was included with the letter. Alere requested the completed form be sent by fax or by email.

For more information: www.inr-care.com

Related Content

Pfizer Announces Positive Topline Results from Phase 3 ATTR-ACT Study
News | Pharmaceuticals | April 06, 2018
Pfizer Inc. announced that the Tafamidis Phase 3 Transthyretin Cardiomyopathy (ATTR-ACT) study met its primary endpoint...
Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

News | Pharmaceuticals | February 01, 2018
February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the Natio
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals | October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals | October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals | September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals | September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals | May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals | May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
Overlay Init